Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibi

No abstract is available for this paper.

• Publication year

  2006

• Venue

  American Heart Journal

• Publication date

  2006-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.AHJ.2006.08.002PMID 17161049
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.

  2006cited by this paper
• Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.

  2004cited by this paper
• Estimating Mean Response as a Function of Treatment Duration in an Observational Study, Where Duration May Be Informatively Censored

  2004cited by this paper
• Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.

  2004cited by this paper
• Interventional cardiology: abstractEfficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: A systematic overview☆

  2004cited by this paper
• Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

  2004cited by this paper
• Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.

  2002cited by this paper
• The SYNERGY trial: study design and rationale.

  2002cited by this paper
• Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

  2002cited by this paper
• Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina.

  2000cited by this paper
• ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: executive summary and recommendations.

  2000cited by this paper
• Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.

  1999cited by this paper
• Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.

  1999cited by this paper
• Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarc

  1998cited by this paper
• Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators.

  1997cited by this paper
• A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.

  1997cited by this paper
• Incidence and Predictors of Bleeding After Contemporary Thrombolytic Therapy for Myocardial Infarction

  1997cited by this paper
• A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.

  1997cited by this paper
• Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.

  1988cited by this paper
• Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase*

  1987cited by this paper
• Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

  1987cited by this paper

• Peri‐Procedural Management of Oral Anticoagulant Therapy in Patients Undergoing Percutaneous Coronary Intervention: Insights from the PERSEO Multicenter Registry

  2025cites this paper
• Initiale Behandlung des akuten Koronarsyndroms: prähospitale Logistik und Notfalltherapie

  2024cites this paper
• Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome

  2023cites this paper
• Therapeutically dosed low molecular weight heparins in renal impairment: a nationwide survey

  2022cites this paper
• Cardiovascular Medications

  2021cites this paper
• Acute Coronary Syndromes in Pregnancy

  2021cites this paper
• Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021

  2021cites this paper
• Diabetes and Cardiovascular Disease

  2019cites this paper
• Adjunctive antithrombotic therapy with primary percutaneous coronary intervention in ST elevation myocardial infarction: ATOLL in perspective.

  2019cites this paper
• Non-ST-Segment Acute Coronary Syndromes.

  2018cites this paper
• Trombosis y anticoagulación en la mujer

  2018cites this paper
• Comparison of enoxaparin and unfractionated heparin in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

  2018cites this paper
• Anticoagulation in Acute Coronary Syndrome-State of the Art.

  2018cites this paper
• Thrombosis and haemostasis : Biological considerations and pharmacological issues

  2017cites this paper
• ST‐elevation acute myocardial infarction in pregnancy: 2016 update

  2017cites this paper
• M 118 – A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes

  2017cites this paper
• Syndromes coronaires aigus avec et sans sus-décalage du segment ST

  2017cites this paper
• Administration of low molecular weight and unfractionated heparin during percutaneous coronary intervention.

  2016cites this paper
• Anticoagulation in coronary intervention.

  2016cites this paper
• Controversies in cardiovascular medicine Anticoagulation in coronary intervention

  2016cites this paper
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014influential citation
• Percutaneous Coronary Intervention in Patients with Atrial Fibrillation: A Study of Factors Affecting Outcome, with a Special Emphasis on Periprocedural Antithrombotic Treatment

  2014cites this paper
• Heparin has No Place as an Anticoagulant in PCI – A Protagonist’s View

  2014cites this paper
• Opposition: Unfractionated heparin should no longer be used in the catheterization laboratory

  2014cites this paper
• Plättchenhemmung und Antikoagulation beim akuten Koronarsyndrom

  2014cites this paper
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cites this paper
• 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cites this paper
• Antithrombotic Issues in Women

  2014cites this paper
• Time from adenosine di-phosphate receptor antagonist discontinuation to coronary bypass surgery in patients with acute coronary syndrome: meta-analysis and meta-regression.

  2013cites this paper
• Gender Differences in Cardiovascular Therapy: Focus on Antithrombotic Therapy and Percutaneous Coronary Intervention

  2013cites this paper
• Safety of pacemaker and implantable cardioverter-defibrillator implantation during uninterrupted warfarin treatment--the FinPAC study.

  2013cites this paper
• Time from adenosine diphosphate receptor antagonist discontinuation to coronary bypass surgery in patients with acute coronary syndrome : Meta-analysis and meta-regression

  2013cites this paper
• Current antithrombotic agents for acute coronary syndromes: focus on bleeding risk.

  2013cites this paper
• Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis

  2012cites this paper
• Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparins.

  2012cites this paper
• Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines

  2012cites this paper
• Percutaneous Coronary Intervention

  2012cites this paper
• MANAGEMENT OF ACUTE CORONARY SYNDROMES ( R MEHRAN , SECTION EDITOR ) Which Antithrombin for Whom ? Identifying the Patient Population that Benefits Most from Novel Antithrombin Agents

  2012cites this paper
• Anticoagulant agents in acute coronary syndromes.

  2011cites this paper
• Bleeding avoidance strategies. Consensus and controversy.

  2011cites this paper
• Management der interventionellen Therapie von Patienten mit akutem Koronarsyndrom und Vorhofflimmern

  2011cites this paper
• The Year in NonST-Segment Elevation Acute Coronary Syndrome

  2011cites this paper
• Comparison of Low Molecular Weight Heparin With Unfractionated Heparin During Percutaneous Coronary Interventions: A Meta-Analysis

  2011cites this paper
• Safety of coronary artery bypass surgery during therapeutic oral anticoagulation.

  2011cites this paper
• Therapiestrategien beim akuten Koronarsyndrom und nach koronaren Interventionen

  2011cites this paper
• Therapiestrategien beim akuten Koronarsyndrom und nach koronaren Interventionen

  2011cites this paper
• Use of low-molecular-weight heparins during percutaneous coronary intervention.

  2011cites this paper
• Impact of race and gender on antithrombotic therapy

  2010cites this paper
• Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: A subgroup analysis from the SYNERGY trial

  2010cites this paper
• The thrombin hypothesis in ACS: a disappointing disconnect between bench data and bedside clinical trials.

  2010cites this paper
• [Concerns on generic enoxaparin use in acute coronary syndrome].

  2010cites this paper
• Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with

  2010cites this paper
• Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome

  2010cites this paper
• How to manage antithrombotic treatment during percutaneous coronary interventions in patients receiving long-term oral anticoagulation: to "bridge" or not to "bridge"?

  2010cites this paper
• The balance between anti-ischemic efficacy and bleeding risk of antithrombotic therapy in percutaneous coronary intervention: a Yin-Yang paradigm.

  2010cites this paper
• The use and limitations of unfractionated heparin.

  2010cites this paper
• Practical Strategies for the Management of Anticoagulation Therapy: Unsolved Issues in the Cardiac Catheterization Laboratory

  2010cites this paper
• Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa Inhibitor

  2010cites this paper
• Part 9: Acute coronary syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations.

  2010cites this paper
• Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician

  2010cites this paper
• Anticoagulation in percutaneous coronary intervention

  2010cites this paper
• Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.

  2010cites this paper
• Unfractionated Heparin and Enoxaparin for the Management of Non-ST-Segment Elevation Acute Coronary Syndromes

  2010cites this paper
• Estratificación del riesgo hemorrágico en el síndrome coronario agudo

  2010cites this paper
• CHAPTER 22 – Diagnosis and Treatment of Complications of Coronary and Valvular Interventions

  2010cites this paper
• Consideraciones sobre el uso de enoxaparina genérica en SCA

  2010cites this paper
• Part 9: Acute coronary syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.

  2010cites this paper
• Recent Publications on Medications and Pharmacy

  2009cites this paper
• [Radial access and management of patients with long-term oral anticoagulation for cardiac catheterization].

  2009cites this paper
• Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study.

  2009influential citation
• Eficacia y seguridad de la enoxaparina en la angioplastia primaria. Análisis comparativo con la heparina no fraccionada

  2009cites this paper
• [Enoxaparin vs. non-fractionated heparin in primary angioplasty of acute myocardial infarction].

  2009cites this paper
• Antiplatelet therapy in percutaneous coronary intervention: A critical review of the 2007 AHA/ACC/SCAI guidelines and beyond

  2009cites this paper
• Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.

  2009cites this paper
• Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics

  2009cites this paper
• In vitro anticoagulation monitoring of low-molecular-weight heparin.

  2009cites this paper
• M118 – A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes

  2009cites this paper
• Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting

  2009cites this paper
• Carta ao Editor

  2009cites this paper
• Strategies to minimize bleeding complications of percutaneous coronary intervention

  2009cites this paper
• Hospitals with and without percutaneous coronary intervention capability: considerations for treating acute coronary syndromes.

  2009cites this paper
• Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

  2009cites this paper
• Safety of diagnostic coronary angiography during uninterrupted therapeutic warfarin treatment.

  2008cites this paper
• Editorial: Antithrombotic management early after mechanical heart valve replacement.

  2008cites this paper
• Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.

  2008cites this paper
• Clinical benefit and practical use of fondaparinux in the invasive management of patients with acute coronary syndromes

  2008cites this paper
• Enoxaparin: a perspective on its use for coronary artery disease

  2008cites this paper
• Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment.

  2008cites this paper
• Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: a prospective randomized pilot trial.

  2008cites this paper
• High-risk Acute Coronary Syndrome Patients with Non-ST-Elevation Myocardial Infarction: Definition and Treatment

  2008cites this paper
• Practical issues on the use of enoxaparin in elective and emergent percutaneous coronary intervention.

  2008cites this paper
• Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

  2008cites this paper
• Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants.

  2008cites this paper
• Acute myocardial infarction

  2008cites this paper
• Economic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndrome

  2008cites this paper
• The year in non-ST-segment elevation acute coronary syndrome.

  2007cites this paper
• ACUITY-PCI: one drug does not fit all.

  2007cites this paper
• Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.

  2007cites this paper
• Recent Publications on Medications and Pharmacy

  2007cites this paper
• Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy

  2007cites this paper